ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP Pivotal phase 3 data show rapid…
The OncoAlert Newsletter is now out for June 23-29, 2023
More than half of the cats at the sanctuary in Shelton, Wash., died of the virus over the past several weeks.
The OncoAlert Newsletter is now out for June 23-29, 2023
Several factors informed HTA outcomes for new cancer medicines. A high ESMO-MCBS score, defined as indicating substantial clinical benefit, increased the likelihood of a positive…
The application of artificial intelligence methods to electronic patient records paves the way for large-scale analysis of multimodal data. Such population-wide data describing deep phenotypes…
Why the AQUILA trial is disappointing for patients and their loved ones
AbstractBACKGROUND AND AIMS. Over the last decade, treatment options for moderate-to-severe ulcerative colitis (UC) have expanded. However, comparative stu
Discussing the tradeoffs in public-health decisions might help us make better choices, write Dr. Christopher Worsham and Dr. Anupam Jena.
Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-mutations.…
